1. Home
  2. PVLA vs PKOH Comparison

PVLA vs PKOH Comparison

Compare PVLA & PKOH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PVLA
  • PKOH
  • Stock Information
  • Founded
  • PVLA 2015
  • PKOH 1907
  • Country
  • PVLA United States
  • PKOH United States
  • Employees
  • PVLA N/A
  • PKOH N/A
  • Industry
  • PVLA Biotechnology: Pharmaceutical Preparations
  • PKOH Industrial Specialties
  • Sector
  • PVLA Health Care
  • PKOH Industrials
  • Exchange
  • PVLA Nasdaq
  • PKOH Nasdaq
  • Market Cap
  • PVLA 253.2M
  • PKOH 282.2M
  • IPO Year
  • PVLA N/A
  • PKOH N/A
  • Fundamental
  • Price
  • PVLA $24.45
  • PKOH $18.35
  • Analyst Decision
  • PVLA Strong Buy
  • PKOH
  • Analyst Count
  • PVLA 7
  • PKOH 0
  • Target Price
  • PVLA $46.29
  • PKOH N/A
  • AVG Volume (30 Days)
  • PVLA 52.4K
  • PKOH 27.9K
  • Earning Date
  • PVLA 05-15-2025
  • PKOH 05-06-2025
  • Dividend Yield
  • PVLA N/A
  • PKOH 2.77%
  • EPS Growth
  • PVLA N/A
  • PKOH 144.68
  • EPS
  • PVLA N/A
  • PKOH 2.26
  • Revenue
  • PVLA N/A
  • PKOH $1,644,000,000.00
  • Revenue This Year
  • PVLA N/A
  • PKOH $1.80
  • Revenue Next Year
  • PVLA N/A
  • PKOH $4.21
  • P/E Ratio
  • PVLA N/A
  • PKOH $6.17
  • Revenue Growth
  • PVLA N/A
  • PKOH N/A
  • 52 Week Low
  • PVLA $11.17
  • PKOH $17.58
  • 52 Week High
  • PVLA $29.27
  • PKOH $34.50
  • Technical
  • Relative Strength Index (RSI)
  • PVLA N/A
  • PKOH 52.74
  • Support Level
  • PVLA N/A
  • PKOH $17.81
  • Resistance Level
  • PVLA N/A
  • PKOH $20.64
  • Average True Range (ATR)
  • PVLA 0.00
  • PKOH 0.75
  • MACD
  • PVLA 0.00
  • PKOH -0.02
  • Stochastic Oscillator
  • PVLA 0.00
  • PKOH 65.08

About PVLA Palvella Therapeutics Inc. Common Stock

Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.

About PKOH Park-Ohio Holdings Corp.

Park-Ohio Holdings Corp is a company, engaged in industrial supply chain logistics and diversified manufacturing business. It operates in three business segments namely Supply Technologies, Assembly Components and Engineered Products. Geographically, the business of the group is amplifying across the region of the United States, Asia, Europe, Canada, Mexico and others. The company derives key revenue from the Supply Technologies segment which includes proactive solutions approach that manages the efficiencies of every aspect of supplying production parts and materials to customers' manufacturing floor, from strategic planning to program implementation.

Share on Social Networks: